Skip to main content
Premium Trial:

Request an Annual Quote

New $11.5M Proteomics Facility Opens in Scotland to Find New Treatments for Superbugs

NEW YORK, Dec. 10 (GenomeWeb News) - A new £6 million ($11.5 million) proteomics facility geared toward finding new treatments for "superbugs" was opened at the University of St. Andrews in Scotlandyesterday.

 

The facility, called the Scottish Structural Proteomics Facility, features robotic equipment, cloning and expression technology, and Invitrogen's flagship Gateway technology. It will serve scientists from 14 research groups, including groups from Glasgowand WarwickUniversities, the USand Japan.

 

"The study of the structure of proteins is essential in the fight against drug resistant bacteria, viruses and parasites, which afflict many people in Scotland and the world," said James Naismith, a professor in chemistry and biomolecular sciences at the University of St. Andrews, who will be overseeing the SSPF projects along with Malcolm White, also of St. Andrews, and Bill Hunter of the University of Dundee.

 

The SSPF was originally funded by a development grant from the Scottish Higher Education Funding Council, a funding agency established by the Universityof St. Andrews' biomolecular sciences department and the faculty of life sciences at the Universityof Dundee.

 

Projects that will be worked on at the SSPF include proteomics studies of methicillin resistant Staphylococcus aureus and the construction of a database of enzymes. The projects aim to identify new targets for antibiotic development and to elucidate how a variety of dangerous human viruses enter into cells and evade immune responses.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.